To our knowledge, we are the first who compared CD68, CD163, CSF-1R and CD206 for TAM detection and assessed their relation with clinicopathological characteristics in a large well-characterized series of intrinsic breast cancer subtypes. This evidence concerns the gene CD163 and breast cancer.